TORL
Financing Round
- Series C
Round Led or Co-led By SymBiosis
TORL BioTherapeutics is a clinical-stage biopharmaceutical company developing antibody-based therapies, including monoclonal antibodies and antibody-drug conjugates, for novel cancer targets. Its lead candidate, TORL-1-23, targets CLDN6+ tumors and is advancing through clinical development with multiple additional ADC and mAb programs in the pipeline.
